Assenagon Asset Management’s CytomX Therapeutics CTMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.63M | Buy |
720,020
+8,566
| +1% | +$19.4K | ﹤0.01% | 796 |
|
|
2025
Q1 | $452K | Buy |
711,454
+111,604
| +19% | +$71K | ﹤0.01% | 1011 |
|
|
2024
Q4 | $618K | Sell |
599,850
-1,044,318
| -64% | -$1.08M | ﹤0.01% | 1149 |
|
|
2024
Q3 | $1.94M | Buy |
1,644,168
+405,669
| +33% | +$479K | ﹤0.01% | 954 |
|
|
2024
Q2 | $1.51M | Buy |
1,238,499
+833,825
| +206% | +$1.02M | ﹤0.01% | 967 |
|
|
2024
Q1 | $882K | Hold |
404,674
| – | – | ﹤0.01% | 1059 |
|
|
2023
Q4 | $627K | Sell |
404,674
-21,247
| -5% | -$32.9K | ﹤0.01% | 1166 |
|
|
2023
Q3 | $549K | Sell |
425,921
-242,111
| -36% | -$312K | ﹤0.01% | 1139 |
|
|
2023
Q2 | $1.15M | Hold |
668,032
| – | – | ﹤0.01% | 912 |
|
|
2023
Q1 | $1.01M | Sell |
668,032
-246,868
| -27% | -$373K | ﹤0.01% | 1015 |
|
|
2022
Q4 | $1.46M | Sell |
914,900
-150,492
| -14% | -$241K | 0.01% | 896 |
|
|
2022
Q3 | $1.55M | Buy |
+1,065,392
| New | +$1.55M | 0.01% | 765 |
|
|
2021
Q4 | – | Sell |
-27,774
| Closed | -$141K | – | 1406 |
|
|
2021
Q3 | $141K | Sell |
27,774
-465,239
| -94% | -$2.36M | ﹤0.01% | 1208 |
|
|
2021
Q2 | $3.12M | Buy |
493,013
+288,872
| +142% | +$1.83M | 0.01% | 556 |
|
|
2021
Q1 | $1.58M | Sell |
204,141
-14,622
| -7% | -$113K | 0.01% | 741 |
|
|
2020
Q4 | $1.43M | Buy |
218,763
+45,887
| +27% | +$301K | 0.01% | 584 |
|
|
2020
Q3 | $1.15M | Sell |
172,876
-80,824
| -32% | -$538K | 0.01% | 722 |
|
|
2020
Q2 | $2.11M | Buy |
+253,700
| New | +$2.11M | 0.01% | 556 |
|
|
2020
Q1 | – | Sell |
-224,640
| Closed | -$1.87M | – | 790 |
|
|
2019
Q4 | $1.87M | Buy |
224,640
+148,740
| +196% | +$1.24M | 0.01% | 421 |
|
|
2019
Q3 | $560K | Sell |
75,900
-48,500
| -39% | -$358K | ﹤0.01% | 640 |
|
|
2019
Q2 | $1.4M | Buy |
+124,400
| New | +$1.4M | 0.01% | 595 |
|
|
2018
Q4 | – | Sell |
-19,638
| Closed | -$363K | – | 983 |
|
|
2018
Q3 | $363K | Buy |
+19,638
| New | +$363K | ﹤0.01% | 693 |
|